CannaPharmaRx Q2 FY26 net loss widens to USD 1.91 million; revenue rises 19.26% to USD 276,218
CPMD•Six-month results and liquidity remain weak
For the six months, revenue rose to USD 903,680; net loss widened to USD 2.29 million.
Liquidity remained strained with USD 555 cash, a USD 31.24 million working-capital deficit; Alberta Ltd. stayed in default under Koze’s royalty agreement.
Quarterly revenue rises while net loss widens
CannaPharmaRx posted Q2 revenue of USD 276,218, up 19.26% year over year; net loss widened to USD 1.91 million.
Gross loss narrowed to USD 138,446 from USD 621,210, on lower inventory impairment charges of USD 218,752.
Other expenses climbed to USD 1.53 million, driven by a USD 1.6 million loss on derivative conversion features.
